Biovaxys Technology Corp (BVAXF)

$0.13 0.00 (-0.92%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 25,100
Avg Vol 81,130
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 41%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
Ventureville
Ventureville Feb. 4 at 3:48 PM
Solid team at $BVAXF $BIOV.CSE Passin brings the finance chops, Kovan the big pharma ops experience, and Dr. Berd the oncology research cred. No wonder they're pushing forward with promising DPX data lately.
0 · Reply
resx18
resx18 Feb. 4 at 3:38 PM
$BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer Feb. 4 at 2:42 PM
$BVAXF
0 · Reply
Golden_Cross
Golden_Cross Feb. 4 at 2:22 PM
$BVAXF Not Your Typical Early-Stage Biotech. It’s a platform-first, licensing-focused company built on decades of prior science https://www.instagram.com/reel/DS2WTkijoS9/ 🚨 120+ Patents 💰 $300 Million Historical R&D 📈 .14 Stock Price 📊 Only $6 Million Market Cap
0 · Reply
Golden_Cross
Golden_Cross Feb. 3 at 7:41 PM
$BVAXF Strong Management team Here!
0 · Reply
wheresdannynow
wheresdannynow Feb. 3 at 6:16 PM
https://www.thenewswire.com/press-releases/1Av7Fw7em-biovaxys-1q2026-r-d-and-collaborative-activity.html BioVaxys jumped on that BARDA RFI early. announced back on Jan 15! DPX fits right in for fast vaccine dev against new bugs, especially with their solid recent cancer data rolling in. $BIOV.CSE $BVAXF
0 · Reply
Davidendz
Davidendz Feb. 3 at 5:14 PM
120+ Patents $300 Million Historical R&D .18 Stock Price Only $6 Million Market Cap $BVAXF $BIOV.CSE
0 · Reply
Ventureville
Ventureville Feb. 3 at 3:04 PM
Look at who they're working with. $BVAXF $BIOV.CSE
0 · Reply
Ventureville
Ventureville Feb. 3 at 3:01 PM
$BIOV.CSE $BVAXF That volume spike near ATH at these depressed prices? Someone's absorbing every share at .22. Jan 16 unlock created forced sellers, but the buying just keeps coming.
0 · Reply
Golden_Cross
Golden_Cross Feb. 3 at 2:51 PM
$BVAXF $BIOV.CSE 🚨 Hot Take: R&D partnerships aren’t just important — They’re the lifeblood of game-changers like BioVaxys. Want to spot the next industry leader? 🔎 Look at who they're working with. Smart teams build with the BEST. The rest get left behind.
1 · Reply
Latest News on BVAXF
No data available.
Ventureville
Ventureville Feb. 4 at 3:48 PM
Solid team at $BVAXF $BIOV.CSE Passin brings the finance chops, Kovan the big pharma ops experience, and Dr. Berd the oncology research cred. No wonder they're pushing forward with promising DPX data lately.
0 · Reply
resx18
resx18 Feb. 4 at 3:38 PM
$BVAXF
0 · Reply
ProfitWhisperer
ProfitWhisperer Feb. 4 at 2:42 PM
$BVAXF
0 · Reply
Golden_Cross
Golden_Cross Feb. 4 at 2:22 PM
$BVAXF Not Your Typical Early-Stage Biotech. It’s a platform-first, licensing-focused company built on decades of prior science https://www.instagram.com/reel/DS2WTkijoS9/ 🚨 120+ Patents 💰 $300 Million Historical R&D 📈 .14 Stock Price 📊 Only $6 Million Market Cap
0 · Reply
Golden_Cross
Golden_Cross Feb. 3 at 7:41 PM
$BVAXF Strong Management team Here!
0 · Reply
wheresdannynow
wheresdannynow Feb. 3 at 6:16 PM
https://www.thenewswire.com/press-releases/1Av7Fw7em-biovaxys-1q2026-r-d-and-collaborative-activity.html BioVaxys jumped on that BARDA RFI early. announced back on Jan 15! DPX fits right in for fast vaccine dev against new bugs, especially with their solid recent cancer data rolling in. $BIOV.CSE $BVAXF
0 · Reply
Davidendz
Davidendz Feb. 3 at 5:14 PM
120+ Patents $300 Million Historical R&D .18 Stock Price Only $6 Million Market Cap $BVAXF $BIOV.CSE
0 · Reply
Ventureville
Ventureville Feb. 3 at 3:04 PM
Look at who they're working with. $BVAXF $BIOV.CSE
0 · Reply
Ventureville
Ventureville Feb. 3 at 3:01 PM
$BIOV.CSE $BVAXF That volume spike near ATH at these depressed prices? Someone's absorbing every share at .22. Jan 16 unlock created forced sellers, but the buying just keeps coming.
0 · Reply
Golden_Cross
Golden_Cross Feb. 3 at 2:51 PM
$BVAXF $BIOV.CSE 🚨 Hot Take: R&D partnerships aren’t just important — They’re the lifeblood of game-changers like BioVaxys. Want to spot the next industry leader? 🔎 Look at who they're working with. Smart teams build with the BEST. The rest get left behind.
1 · Reply
wheresdannynow
wheresdannynow Feb. 2 at 9:23 PM
$BIOV.CSE $BVAXF
0 · Reply
wheresdannynow
wheresdannynow Feb. 2 at 9:22 PM
So many reasons to love $BIOV.CSE $BVAXF right now. Patents. Pipeline. Partnerships. Cleaned-up balance sheet. Tiny market cap. This is not ignored because it’s bad, it’s ignored because it’s early. When biotech moves, it does not ask for permission.
0 · Reply
Golden_Cross
Golden_Cross Feb. 2 at 5:59 PM
$BVAXF ~ So many reasons to love this stock right now. Too many reasons to like it. Too much upside to ignore. While others sleep on it, I’m doubling down. Winners see opportunity before headlines.
1 · Reply
Golden_Cross
Golden_Cross Feb. 2 at 3:47 PM
$BVAXF $BIOV.CN Not Your Typical Early-Stage Biotech. It’s a platform-first, licensing-focused company built on decades of prior science https://www.instagram.com/reel/DS2WTkijoS9/ 🚨 120+ Patents 💰 $300 Million Historical R&D 📈 .14 Stock Price 📊 Only $6 Million Market Cap
0 · Reply
Ventureville
Ventureville Feb. 2 at 3:44 PM
Volume's been insane lately, hitting 90K+ days at .22 with complete response data in hand. Something's brewing before the next gate opens, probably the OS readout or licensing terms. $BIOV.CSE $BVAXF
0 · Reply
resx18
resx18 Feb. 2 at 3:03 PM
$BVAXF
0 · Reply
Golden_Cross
Golden_Cross Feb. 2 at 2:09 PM
$BVAXF BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab https://finance.yahoo.com/news/biovaxys-reports-positive-clinical-study-130000795.html
0 · Reply
Golden_Cross
Golden_Cross Feb. 1 at 12:37 PM
$BVAXF Biovaxys Investor Q&A Replay Link: https://x.com/SuperRobotGX/status/2016983512671273306
0 · Reply
Marketing_2Masses
Marketing_2Masses Jan. 30 at 9:31 PM
$BVAXF Just caught yesterday’s X Spaces on BioVaxys Technology Corp. Mind-blowing deep dive into Phase 2 bladder cancer data: complete responses in advanced, tough-to-treat cases — huge validation for the DPX™ platform! Big hints dropped on expanding partnerships: • Zoetis (animal health giant) • Sona Nanotech (gold nanorod hyperthermia synergy) These could supercharge DPX™ across oncology & beyond. Biotech revolution loading — $BIOV positioning as a next-gen immunotherapy leader! /NFA https://x.com/cs_marketinginc/status/2017228733577662570?s=46
0 · Reply
Davidendz
Davidendz Jan. 30 at 8:30 PM
Volume near monthly ATH while price sits at .22? Classic disconnect. Retail stacking 100K+ blocks at support while Jan 16 unlock sellers fade out, that is your tape telling you smart money is quietly positioning before the next leg. Science does not wait for charts to catch up. $BIOV.CSE $BVAXF
0 · Reply
Golden_Cross
Golden_Cross Jan. 30 at 8:29 PM
$BVAXF Buy Volume: 369,610 Sell volume: 147,000
0 · Reply
the_goat1
the_goat1 Jan. 30 at 7:42 PM
$BVAXF Low liquidity churn is just a gift for anyone paying attention. Not selling for pennies when the platform is worth billions. 💎🙌
0 · Reply